| Duruisseaux, Michael |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
| Active, not recruiting | 2 | 55 | Europe | Nivolumab, BMS-936558-01 | European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation | Thymoma Type B3, Thymic Carcinoma | 12/23 | 07/24 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
| Completed | N/A | 209 | Europe | CANUT support, Anthropometric measures, Prehension strength measurement, QVA Questionnaire, QLQ C30 Questionnaire, Scratch & Snif Test, Taste Strip Test, 24 H feed back questionnaire, Condiment questionnaire, Tobacco questionnaire, Nutrition interview | Hospices Civils de Lyon | Breast Cancer, Gynecologic Cancer, Bronchial Cancer, Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy | 09/23 | 09/23 | | |
| Recruiting | N/A | 260 | Europe | Blood sampling | Hospices Civils de Lyon | All Types of Solid Cancer | 05/28 | 05/28 | | |
| Recruiting | N/A | 600 | Europe | Solicitation for lung cancer screening, added exams to the usual lung cancer screening | Hospices Civils de Lyon | Lung Cancer | 09/24 | 09/24 | | |
DRACONIS, NCT06781905: Description of Neurocognitive and Psychiatric Disorders Associated with Targeted Therapies Used in the Treatment of Lung Cancers with ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway |
|
|
| Not yet recruiting | N/A | 20 | Europe | Assessments of neuropsychiatric, neurocognitive and psychosocial alterations | Hospices Civils de Lyon | Metastatic Lung Cancer, Metastatic Lung Cancer with ALK/ROS1 Fusion | 05/27 | 05/27 | | |
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients |
|
|
| Recruiting | N/A | 410 | Europe | Blood draws | Hospices Civils de Lyon | Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma | 01/28 | 01/28 | | |
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy |
|
|
| Recruiting | N/A | 100 | Europe | Tele-monitoring | Hospices Civils de Lyon | Melanoma, Lung Cancer, Renal Cancer | 11/28 | 11/28 | | |
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE |
|
|
| Recruiting | N/A | 2000 | Europe | Estimation of the incidence of the irAE | Hospices Civils de Lyon | Cancer | 07/29 | 07/29 | | |
| LARAMASSE, Mathieu |
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy |
|
|
| Recruiting | N/A | 100 | Europe | Tele-monitoring | Hospices Civils de Lyon | Melanoma, Lung Cancer, Renal Cancer | 11/28 | 11/28 | | |
